Navigation Links
Experimental Drugs Show Promise Against Prostate Cancer
Date:5/31/2013

FRIDAY, May 31 (HealthDay News) -- Researchers have identified a new class of drugs that show promise for treating advanced prostate cancer. The drugs, known as peptidomimetics, interfere with the signaling necessary for prostate cancer cells to grow, according to a new study.

Prostate cancer depends upon the actions of androgens, such as the "male" hormone testosterone. Androgens activate androgen receptors, resulting in a signal that causes prostate cancer cells to grow.

To stop tumor growth, men with prostate cancer have been treated with drugs to block the production of androgens or block the receptor where androgens bind. However, tumors can grow despite this treatment because of mutations in androgens or receptors.

In the latest study, published online May 28 in Nature Communications, a team of researchers led by Dr. Ganesh Raj, associate professor of urology at UT Southwestern Medical Center at Dallas, found the nontoxic peptidomimetic agents could disrupt androgen-receptor signaling and prevent tumor growth.

When tested in mouse and human tissue models, the drugs blocked the activity of androgens by attacking the protein in a different spot from where the androgen binds, the researchers explained. As a result, prostate cancer cells do not receive the signal to grow -- even when the androgen receptor is activated.

"We are hopeful that this novel class of drugs will shut down androgen-receptor signaling and lead to added options and increased longevity for men with advanced prostate cancer," Raj, the study's senior author, noted in a university news release.

The researchers noted more testing is needed before the drugs could progress to clinical trials involving humans. Results obtained in laboratory experiments are not always replicated in humans.

"Most drugs now available to treat advanced prostate cancer improve survival rates by three or four months," Raj added. "Our new agents may offer hope for men who fail with the current drugs."

More information

The U.S. National Cancer Institute has more about treatment for prostate cancer.

-- Mary Elizabeth Dallas

SOURCE: UT Southwestern, news release, May 28, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
2. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
3. Experimental Drug for Hepatitis C Promising, Studies Show
4. Experimental Vaccine Shows Promise for Ovarian Cancer
5. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
6. Experimental Staph Vaccine Fails to Work, Study Finds
7. Experimental Drug May Work Against Hepatitis C
8. Experimental Alzheimers Drug Shows Promise, Study Finds
9. Experimental Vitiligo Treatment Shows Promise in Mice
10. Harmful effects of bisphenol A proved experimentally
11. Experimental agent briefly eases depression rapidly in test
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Experimental Drugs Show Promise Against Prostate Cancer
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... Tanya ... Exilis in Lone Tree, CO, at Atagi Plastic Surgery and Skin Aesthetics. , ... a potent combination of radiofrequency and ultrasound energy. Smoother, younger-looking skin is revealed on ...
(Date:8/17/2017)... ... August 17, 2017 , ... Inc. Magazine Unveils 36th Annual List of ... Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. magazine ... prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look ...
(Date:8/17/2017)... VA (PRWEB) , ... August 17, 2017 , ... ... for Great Employers , an international competition, were announced today. The awards recognize ... products and suppliers who help to create and drive great places to work. ...
(Date:8/16/2017)... ... ... Blue Health Intelligence (BHI) announced today that Dr. Alan Spiro joined ... 30 years of clinical, healthcare IT, value-based care, and change management experience to BHI ... am thrilled to welcome Dr. Spiro to BHI,” said Swati Abbott, CEO of Blue ...
(Date:8/16/2017)... ... ... Any Lab Test Now® is thrilled to announce its groundbreaking premiere ... annual Inc. 5000 , the most prestigious compilation of the nation's fastest-growing private ... American economy’s most dynamic segment — its independent small and midsized businesses. , Any ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve ... his tenure, Paul has served us in multiple leadership roles ... Pharmacy in Jun. 2015 and has provided decisive, strategic leadership ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
Breaking Medicine Technology: